PPARG and obesity disorder: Furthermore, ellagic acid at 50 μM, 10 and 20 μM punicalagin, and particularly 50 μM of urolithin A have been shown to prevent metabolic diseases like obesity and diabetes by inhibiting lipase, α-glucosidase, and dipeptidyl peptidase-4 activity, and by reducing triglyceride accumulation and adipocyte formation through reducing adiponectin, PPARγ, GLUT4, and FABP4 expression in 3T3-L1 adipocytes [32].